Author

Annegret Van der Aa 1

1 Galapagos NV,Mechelen,Belgium

EFFECT OF DISEASE DURATION AND LOCATION ON CLINICAL REMISSION IN CROHN’S DISEASE PATIENTS TREATED WITH FILGOTINIB, A SELECTIVE JAK1 INHIBITOR: POST-HOC ANALYSIS FROM THE PHASE 2 FITZROY STUDY

Severine Vermeire, Annegret Van der Aa, Corinne Jamoul, Chantal Tasset, Pille Harrison, Geert R. D'Haens

FILGOTINIB, A SELECTIVE JAK1 INHIBITOR, INDUCES CLINICAL REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE CROHN?S DISEASE: FINAL ANALYSIS OF THE PHASE 2 FITZROY STUDY

Severine Vermeire, Stefan Schreiber, R. Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Eugen-Adrian Goldis, Maria Wisniewska Jarosinska, Andrey Baranovsky, Robert Sike, Kremana Stoyanova, Chantal Tasset, Annegret Van der Aa, Pille Harrison

HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JAK1 INHIBITOR FILGOTINIB IN ACTIVE CROHN’S DISEASE: RESULTS FROM FITZROY STUDY

Walter Reinisch, Geert R. D'Haens, Gert De Hertogh, Annegret Van der Aa, Jenny Zhang, Chantal Tasset, Chohee Yun, Adrian Serone, Brian G. Feagan, William Sandborn, Severine Vermeire

Item 1 - 3 / 3
1